Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.08.2013 | main topic

Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients

verfasst von: Katherine Boyd, MD, Sofia M Shea, MD, James Patterson, MD

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Survival of solid organ transplant patients has been prolonged, leading to increased incidence of non-melanoma skin cancers. Metastatic squamous cell carcinoma is an increasing problem in these patients. This paper reviews the evidence available for the treatment of advanced squamous cell carcinoma with the epidermal growth factor receptor inhibitor, cetuximab.
Vorheriger Artikel Subungual acrolentiginous amelanotic melanoma treated with amputation of the distal and middle phalanges

Nächster Artikel Cutaneous side effects of vemurafenib: a case report and discussion
Literatur
Jensen P, Hansen S, Moller B, Leivestad T, et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol. 1999;40:177–86.PubMedCrossRef
Ritchie SA, Patel MJ Miller SJ. Therapeutic options to decrease actinic keratosis and squamous cell carcinoma incidence and progression in solid organ transplant recipients: a practical approach. Dermatol Surg. 2012;38:1604–21.PubMedCrossRef
Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8:342–6.PubMed
Martinez JC, Otley CC, Okuno SH, Foote RL, Kasperbauer JL. Chemotherapy in the setting of advanced cutaneous squamous cell carcinoma in organ transplant recipients: theoretical and practical considerations. Dermatol Surg. 2004;30:679–86.PubMedCrossRef
Ch’ng S, Low I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squamous cell carcinoma. Hum Pathol. 2008;39:344–9.PubMedCrossRef
Cranmer LD, Engelhardt C, Morgan SS. Treatment of unresectable and metastatic cutaneous squamous cell carcinoma. Oncologist. 2010;15:1320–8.PubMedCrossRef
Preneau S, Rio E, Brocard A, Peuvrel L, Nguyen JM, Quereux G, Dreno B. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2013;1–4 (Epub ahead of print).
Kies MS, Holsinger FC, Lee JJ, William WN Jr, Glisson BS, Lin HY, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010;28:8–14.PubMedCrossRef
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.PubMedCrossRef
Maubec E, Petrow P, Duvillard P, et al. Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: final results of a phase II multicenter study (abstract). J Clin Oncol. 2010;28:8510.
Kalapurakal SJ, Malone J, Robbins KT, Buescher L, Godwin J, Rao K. Cetuximab in refractory skin cancer treatment. J Cancer. 2012;3:257–61.PubMedCrossRef
Bauman JE, Eaton KD, Martins RG. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab. Arch Dermatol. 2007;143:889–92.PubMedCrossRef
Suen JK, Bressler L, Hord SS, et al. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab. Anticancer Drugs. 2007;18:827–92.PubMedCrossRef
Wollina U. Cetuximab in non-melanoma skin cancer. Expert Opin Biol Ther. 2012 Jul;12(7):949–56.PubMedCrossRef
Giacchero D, Barriere J, Benezery K, Guillot B, Dutriaux C, Mortier L, Lacour J-P, Thuss A, Peyrade F. Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma—a report of eight cases. Clin Oncol. 2011;23:716–21.CrossRef
Mecca C, Ponzetti A, Caliendo V, Ciuffreda L, Lista P. Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel. Eur J Dermatol. 2012;22(6):758–61.PubMed
Vaccaro M, Barbuzza O, Pollicino A, Guarneri C. Acneiform eruption following molecular targeted chemotherapy. Intern Med J. 2011 Apr;41(4):361–2.PubMedCrossRef
Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Durgs Today 2005;41(2)107–27.CrossRef
Valeriani M, Muni R, Osti MF, De Sanctis V, Minniti G, Ardito F, Maurizi Enrici R. Acute toxicity in 14 patients with locally advanced head and neck squamous cell carcinoma treated with concurrent cetuximab and radiotherapy. Radio Med. 2012;117:125–32.CrossRef
Bonner JA, Harai PM, Girait J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567–78.PubMedCrossRef
Mydin AR, Armstrong JG. Radiotherapy plus cetuximab is safe in a head and neck cancer patient on immunosuppressants for liver transplant. J Clin Oncol 2007 Feb;365–6.
Leard LE, Cho BK, Jones KD, Hays SR, Tope WD, Golden JA, Hoopes CW. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab. J Heart Lung Transplant. 2007;26:1340–4.PubMedCrossRef
Metadaten
Titel
Cetuximab for treatment of advanced squamous cell carcinoma in solid organ transplant recipients
verfasst von
Katherine Boyd, MD
Sofia M Shea, MD
James Patterson, MD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-013-0213-5

Weitere Artikel der Ausgabe 15-16/2013

Atypical fibroxanthoma—a diagnosis of exclusion!

  • case report

Merkelzellkarzinom: eine Überprüfung und Aktualisierung über die Pathogenese, Diagnose und Therapieansätze

  • main topic

Subungual acrolentiginous amelanotic melanoma treated with amputation of the distal and middle phalanges


  • main topic

Skin cancer treatment options: new horizons and promises for the future

  • editorial

Advanced basal cell carcinoma

  • main topic

Nachruf Prof. Dr. Walter H. Hörl 11.7.1945 – 25.6.2013

  • nachruf